



Draft 10/10/2015

Vienna, October 13, 2015

Biosimilars:

same quality, lower price, improved patient access

Arnold G. Vulto FCP PharmD PhD

Professor of Hospital Pharmacy & Practical Therapeutics

Erasmus University Medical Center Rotterdam

The Netherlands

a.vulto@erasmusmc.nl







- Introduction and Perspective
- Learnings from generic medicines
- Is the same true for biosimilars?
 - Variability by region and molecule
- Why Norway is succesful
- A safe future? Potential threats
- Take home message





- I declare no personal financial interest in any pharmaceutical bussiness
- I entertain friendly relationships with all innovative and generic / biosimilar companies
- As a co-founder I have a societal but not financial interest in the advocacy of cost-effective treatments via the Generics & Biosimilar Initiative (GaBI)
- My employer Erasmus University Hospital receives any honoraria (advisory boards, speakers honoraria) if they let me speak at scientific or commercial meetings.



Generic medicines succesfully drive the market

 The expectations of the biosimilars-market are driven by the success of the generics market



Marketeffects of the introduction of generic medicines

- 3 categories
 - I. No of users increase, total cost decrease
 - 2. No of users stabilises, total cost decrease
 - 3. No of users decrease, total cost decrease faster

Ref: Dylst, Vulto & Simoens (2015) Exp Rev Pharmacoecon Outcomes Res Based on GIP Prescription Database, The Netherlands





Erasmus MC

zafing

Category 1: Number of users increase, total cost decrease (mind X-axis: Millions of Euros)

Figure 1. Evolution of total costs and total number of users for five active substances of which the total number of users increased after generic entry whereas the total costs decreased. The vertical line indicates the time of generic entry.

Total costs

Total users





- Category 2:
- Number of users stabilises, total cost decreases (dramatically)

Figure 2. Evolution of total costs and total number of users for five active substances of which the total number of users remained constant after generic entry, whereas the total costs decreased. The vertical line indicates the time of generic entry.





- Category 3:
- Number of users is decreasing (shift in therapy), but cost is decreasing stronger

Figure 3. Evolution of total costs and total number of users for five active substances of which the total number of users decreased after generic entry, whereas the total costs decreased. The vertical line indicates the time of generic entry.





- Introduction and Perspective
- Learnings from generic medicines
- Is the same true for biosimilars?
 - Variability by region and molecule
- Why Norway is succesful
- A safe future? Potential threats
- Take home message





Three generations of therapeutic proteins

- Generation 1: substitution products
 - Hormones like growth factors or insulin
 - Effect visible / measurable in hours or days
- Generation 2: proteins with a specific pharmacological effect
 - Like TNF-alfa inhibitors
 - Effect only visible after some time, but not in all patients
- Generation 3: proteins with a less concrete clinical effect
 - "Targeted therapies" in oncology
 - The effect is a statistical chance some time in the future (survival)



Uptake of first generation biosimilars



It varies by therapeutic area and by region



Biosimilar penetration (% of treatment days 2013)





But total cost may have increased

Relative change in the medicine cost 2006 vs 2013, (price x volume)



Reasons for variation (source: IMS Health)

Stakeholder landscape and treatment cycle are the key determinants



- Payer-driven market access (e.g. Tender, step-wise algorithms)
- Price-driven competition
- Acute treatment and/or frequent cycling among therapies

 Complex stakeholder landscape with higher physician influence

Erasmus MC

zamo

T5

ITALY

T6

- Competition based on multiple marketing levers
- Chronic treatment and/or long therapeutic cycles





IMS INSTITUTE

Differences in the use of biosimilars are not just explained by epidemiology and disease factors, but reflect local adoption of treatment practices and guidelines influenced by funding decisions and payer actions.

This highlights the need for physician education and introduction of national policies to increase the use of biosimilars.

October 2014

Assessing biosimilar uptake and competition in European markets





Granulocyte Colony Stimulating Factor (GCSF - filgrastim)

in EU (source: IMS 2014)





Source: IMS Health, Monthly Standard Units Daily G-CSF



Granulocyte Colony Stimulating Factor (GCSF - filgrastim) in Australia (source: IMS 2014)



First generation biosimilars: increased access in EU?

- Different molecules show different patterns
- GCSF: + 100% (market share biosimilars: 20%)
- Growth hormone: +44% (market share biosimilar: 9%)
- Erythropoetin: + 16% (market share biosimilars: 15%)

(more data to be released by EU-commission end 2015)





- Introduction and Perspective
- Learnings from generic medicines
- Is the same true for biosimilars?
 - Variability by region and molecule
- Why Norway is succesful
- A safe future? Potential threats
- Take home message



Erasmus MC zafing

Infliximab biosimilar in Norway

Patient	Tender year	Remicade	Remsima	Savings	Savings (%)
Rheumatoid arthritis, 70 kg, one year treatment	2014	84 000 NOK 10 500 EUR 14 000 USD	51 000 NOK 6 400 EUR 8 500 USD	33 000 NOK 4 100 EUR 5 500 USD	39%
	2015	83 400 NOK 9 700 EUR 11 000 USD	26 000 NOK 3 000 EUR 3 400 USD	57 400 NOK 6 700 EUR 7 600 USD	69 %

Steinar Madsen, EGA Biosimilar Meeting 2015

Market share biosimilar infliximab in Norway (based on vials sold)





Steinar Madsen, EGA Biosimilar Meeting 2015

2014/2015



What were the succes factors in Norway

- An advisory board with most of the (clinical) opinion leaders were involved in deciding on the pre-tender conditions
- To start with, only new patients will receive the biosimilar
- After each year: new tender, again for NEW patients (existing patients will not be changed); further cost reduction
- Savings will be invested in:
 - Treating more patients for less money
 - Trials in support of unresolved areas like extrapolated indications and controlled switching
- This is a win-win for everybody (Torfinn Aanes, National Procurement Board)





- Introduction and Perspective
- Learnings from generic medicines
- Is the same true for biosimilars?
 - Variability by region and molecule
- Why Norway is succesful
- A safe future? Potential threats
- Take home message





What is there to come?

																																																1	
1	Ē	i.			Ē	i.	1	2	f		Ē		Ē	ŝ		Ē	i.		2	Ē	ŝ			1	i.		1	Ē	ŝ		ĩ			2					Ē			ŝ			ŝ		Ē		

- August 2015: 3 biosimilars submitted for registration (EMA)
 - Educated guess: etanercept, infliximab, ??



Erasmus MC



These products will loose market exclusivity by 2020

Global Sales (MAT 12/2014), US\$ billion



EU expiry date	US expiry date
2018	2016
2014	2015
2015	2028 (extended)
2015	2018
Expired	Expired
Expired	2018
2019	2019
2014	2019
2015	2016
2017	2014
2015	2015
2016	2016

Not considered existing biosimilars such as Epoetin Alfa expired in EU, but still patent protected in the US



Expectations in the UK

Brooming our of potonical launon auto for any malouton
--

2015	page	2016	page	2017	page
insulin glargine (LY2963016)	68	insulin glargine (MK-1293)	69	insulin glargine (Basalog)	69
follitropin alfa (XM 17)	70	somatropin	69	infliximab (BOW-015)	71
		etanercept (GP2015)	70	etanercept (CHS-0214)	71
		etanercept (SB4)	70	rituximab (MabionCD20)	72
		infliximab (SB2)	71	Infliximab (PF 06438179)	72
		rituximab (BI 695500)	74	trastuzumab (CT-P6)	73
				pegfilgrastim (LA-EP2006)	73
				pegfilgrastim (Neupeg/Pegasta)	73
				trastuzumab (ABP 980)	74
				trastuzumab (PF-05280014)	74
				rituximab (PF-05280586)	75

NHS Prescribing Outlook 2015





- More biosimilars to come
- More biosimilars will induce more market pressure
 - Potential risk: price erosion, threat for sustainability
- With insuline glargylin biosimilars enters the family physician market
 - Huge educational effort required
- More countries adapt EU biosimilar framework
 - Without capacity for the rigorous assessment
 - Risk of sub-standard products slipping through, potentially damaging biosimilar reputation





- Introduction and Perspective
- Learnings from generic medicines
- Is the same true for biosimilars?
 - Variability by region and molecule
- Why Norway is succesful
- A safe future? Potential threats
- Take home message





Take home message

- - Uptake of biosimilars is much slower than of generic medicines
 - Cost per treatment day will go down
 - But total cost may grow due to increased access
 - Payers can play a crucial role in driving the market
 - For biosimilar insulin massive education required
 - Physicians very slow in adopting biosmilars
 - Based on experience with 2nd generation & indication extrapolation
 - For 3rd generation huge educational effort required



www.gabionline.net (14a10)

<u>www.gabi-journal.net</u>



Generics and Biosimilars Initiative Building trust in cost-effective treatments www.gabionline.net

GaBI is supporting you

Please support GaBI



Thank you for your attention



Contact: a.vulto@erasmusmc.nl



	0																																						





What are we talking about?

- The only true definition of a biosimilar as of October 2015:
 - A biosimilar is a pharmaceutical product, that as such has been licensed via the WHO regulatory pathway (=minimum global standard)
- What does that mean?
 - It is a copy of an already licensed biotech-drug, for which similarity has been proven in an extensive *comparability exercise*, encompassing physical, chemical, biological and pharmacological properties, including efficacy and safety
- This excludes all kinds of *bio-questionables* in existence in other regions of the world that have not been endorsed via the WHO pathway as a biosimilar.
 Reference to such products as if biosimilars may be inferior is thus WRONG.

Erasmus MC



Most large companies are now on the biosimilar bandwagon

- Pfizer / Hospira: "big five" *
- Amgen: "big five" and more
- MSD
- Merck Serono
- Sandoz: "big five"
- TEVA: "big five"
- Samsung / Biogen: "big five"
- Baxter
- Boehringer Ingelheim "big five"

"Big Five": adalimumab, etanercept, infliximab, rituximab, trastuzumab